Image

BIMZELX is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.1
NICE recommendation applies to severe disease (PASI ≥ 10 or DLQI > 10) and when the disease has not responded to other systemic treatments, or when they are contraindicated or not tolerated.2
References
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.
Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.
Help us to grow our resource the way you want it to grow.